Is the metalloendopeptidase EC 3.4.24.15 (EP24.15), the enzyme that cleaves luteinizing hormone-releasing hormone (LHRH), an activating enzyme?

Reproduction

Volumn 139, Issue 2, 2010, Pages 319-330

  Cleverly, Kirsty ^a,b,c   Wu, T John ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c NEWHAM UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NEOENDORPHIN; ANGIOTENSIN I; ANGIOTENSIN II; ARGIPRESSIN; BRADYKININ; CALCITONIN GENE RELATED PEPTIDE ALPHA; CALCITONIN GENE RELATED PEPTIDE BETA; DYNORPHIN A; DYNORPHIN B; GONADORELIN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; INTERMEDIN; LEUPRORELIN; METALLOENDOPEPTIDASE EC 3.4.24.15; METALLOPROTEINASE; NEUROPEPTIDE; NOCICEPTIN; OXYTOCIN; PEPTIDE FRAGMENT; SUBSTANCE P; TAMOXIFEN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; ZINC;

BIOLOGICAL ACTIVITY; BREAST; BREAST CANCER; DRUG EFFECT; HORMONE METABOLISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN PROCESSING; REGULATORY MECHANISM; REPRODUCTION; REVIEW;

ANIMALS; CELL PROLIFERATION; FEMALE; GONADOTROPIN-RELEASING HORMONE; GONADS; HUMANS; HYDROLYSIS; HYPOTHALAMUS; MALE; MAMMARY GLANDS, HUMAN; METALLOENDOPEPTIDASES; PEPTIDE FRAGMENTS; PITUITARY GLAND; PROSTATE; PROTEIN PRECURSORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, LHRH; REPRODUCTION; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

MAMMALIA;

EID: 75149116594     PISSN: 14701626     EISSN: 17417899     Source Type: Journal    
DOI: 10.1530/REP-09-0117     Document Type: Review

References (125)

1. Acker GR, Molineaux C & Orlowski M 1987 Synaptosomal membrane bound form of endopeptidase-24.15 generates Leu-enkephalin from dynorphin 1-8, alpha- and beta-neoendorphin, and Met-enkephalin from Met-enkephalin-Arg6-Gly7- Leu8. Journal of Neurochemistry 48 284-292.
2. Arencibia JM & Schally AV 2000 Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line. International Journal of Oncology 16 1009-1013.
3. Bahk JY, Hyun JS, Lee H, Kim MO, Cho GJ, Lee BH & Choi WS 1998 Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells. Urological Research 26 259-264.
4. Baldwin EL, Wegorzewska IN, Flora M & Wu TJ 2007 Regulation of type II luteinizing hormone-releasing hormone (LHRH-II) gene expression by the processed peptide of LHRH-I, LHRH-(1-5) in endometrial cells. Experimental Biology and Medicine 232 146-155.
5. Barros M, De Souza Silva MA, Huston JP & Tomaz C 2002 Anxiolytic-like effects of substance P fragment (SP(1-7)) in non-human primates (Callithrix penicillata). Peptides 23 967-973.
6. Bennett HPJ & McMartin C 1979 Peptide hormones and their analogues: distribution, clearance from the circulation, and inactivation in vivo. Pharmacological Reviews 30 247.
7. Bennett LA, Johnson JM, Stephens DP, Saad AR & Kellogg DL Jr 2003 Evidence for a role for vasoactive intestinal peptide in active vasodilatation in the cutaneous vasculature of humans. Journal of Physiology 552 223-232.
8. Botelho-Santos GA, Sampaio WO, Reudelhuber TL, Bader M, Campagnole-Santos MJ & Souza dos Santos RA 2007 Expression of an angiotensin-(1-7)-producing fusion protein in rats induced marked changes in regional vascular resistance. American Journal of Physiology. Heart and Circulatory Physiology 292 H2485-H2490.
9. Bourguignon JP, Alvarez Gonzalez ML, Gerard A & Franchimont P 1994 Gonadotropin releasing hormone inhibitory autofeedback by subproducts antagonist at N-methyl-D-aspartate receptors: a model of autocrine regulation of peptide secretion. Endocrinology 134 1589-1592.
10. Bramley TA, Menzies GS & Baird DT 1985 Specific binding of gonadotrophin-releasing hormone and an agonist to human corpus luteum homogenates: characterization, properties, and luteal phase levels. Journal of Clinical Endocrinology and Metabolism 61 834-841.
11. Bull P, Morales P, Huyser C, Socias T & Castellon EA 2000 Expression of GnRH receptor in mouse and rat testicular germ cells. Molecular Human Reproduction 6 582-586.
12. Casan EM, Raga F, Bonilla-Musoles F & Polan ML 2000 Human oviductal gonadotropin-releasing hormone: possible implications in fertilization, early embryonic development, and implantation. Journal of Clinical Endocrinology and Metabolism 85 1377-1381.
13. Chappell MC, Modrall JG, Diz DI & Ferrario CM 2004 Novel aspects of the renal renin-angiotensin system: angiotensin-(1-7), ACE2 and blood pressure regulation. Contributions to Nephrology 143 77-89.
14. Choi JH, Gilks CB, Auersperg N & Leung PC 2006 Immunolocalization of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary. Journal of Clinical Endocrinology and Metabolism 91 4562-4570.
15. Chou CS, Beristain AG, MacCalman CD & Leung PC 2004 Cellular localization of gonadotropin-releasing hormone (GnRH) I and GnRH II in first-trimester human placenta and decidua. Journal of Clinical Endocrinology and Metabolism 89 1459-1466.
16. Clayton RN, Eccleston L, Gossard F & Morel G 1992 Rat granulosa cells express the gonadotropin-releasing hormone gene: evidence from in situ hybridisation. Journal of Molecular Endocrinology 9 189-195.
17. Conn PM & Crowley WF Jr 1994 Gonadotropin-releasing hormone and its analogs. Annual Review of Medicine 45 391-405.
18. Crack PJ, Wu TJ, Cummins PM, Ferro ES, Tullai JW, Glucksman MJ & Roberts JL 1999 The association of metalloendopeptidase EC 3.4.24.15 at the extracellular surface of the AtT-20 cell plasma membrane. Brain Research 835 113-124.
19. Cummins PM, Pabon A, Margulies EH & Glucksman MJ 1999 Zinc coordination and substrate catalysis within the neuropeptide processing enzyme endopeptidase EC 3.4.24.15. Identification of active site histidine and glutamate residues. Journal of Biological Chemistry 274 16003-16009.
20. Cunha FM, Berti DA, Ferreira ZS, Klitzke CF, Markus RP & Ferro ES 2008 Intracellular peptides as natural regulators of cell signaling. Journal of Biological Chemistry 283 24448-24459.
21. Dahms P & Mentlein R 1992 Purification of the main somatostatin degrading proteases from rat and pig brains, their action on other neuropeptides and their identification as endopeptidases 24.15 and 24.16. European Journal of Biochemistry 208 145-154.
22. De Camargo AC, Da Fonseca MJ, Caldo H & De Morais Carvalho K 1982 Influence of the carboxyl terminus of luteinizing hormone-releasing hormone and bradykinin on hydrolysis by brain endo-oligopeptidases. Journal of Biological Chemistry 257 9265-9267.
23. Dong KW, Yu KL & Roberts JL 1993 Identification of a major up-stream transcription start site for the human progonadotropin-releasing hormone gene used in reproductive tissues and cell lines. Molecular Endocrinology 7 1654-1666.
24. Emons G & Schally AV 1994 The use of luteinizing hormone releasing hormone agonists and antagonists in gynecological cancers. Human Reproduction 9 1364-1379.
25. Fekete M, Wittliff JL & Schally AV 1989 Characteristics and distribution of receptors for [D-Trp6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor and sex steroids in 500 biopsy samples of human breast cancer. Journal of Clinical Laboratory Analysis 3 137-147.
26. Gard PR 2008 Cognitive-enhancing effects of angiotensin IV. BMC Neuroscience 9 S15.
27. Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN & Leung HY 2005 Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer. Journal of Pathology 206 205-213.
28. Gore AC 2002 GnRH: The Master Molecule of Reproduction. Norwell, MA: Kluwer Academic Publishers.
29. Grundker C, Volker P & Emons G 2001 Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Endocrinology 142 2369-2380.
30. Handelsman DJ & Swerdloff RS 1986 Pharmacokinetics of gonadotropin-releasing hormone and its analogs. Endocrine Reviews 7 95-105.
31. Harris N, Dutlow C, Eidne K, Dong KW, Roberts J & Millar R 1991 Gonadotropin-releasing hormone gene expression in MDA-MB-231 and ZR-75-1 breast carcinoma cell lines. Cancer Research 51 2577-2581.
32. Harrison GS, Wierman ME, Nett TM & Glode LM 2004 Gonadotropin-releasing hormone and its receptor in normal and malignant cells. Endocrine-Related Cancer 11 725-748.
33. Hasan AA, Amenta S & Schmaier AH 1996 Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. Circulation 94 517-528.
34. Hasan AA, Rebello SS, Smith E, Srikanth S, Werns S, Driscoll E, Faul J, Brenner D, Normolle D, Lucchesi BR et al. 1999 Thrombostatin inhibits induced canine coronary thrombosis. Thrombosis and Haemostasis 82 1182-1187.
35. Hsueh AJ & Jones PB 1982 Regulation of ovarian granulosa luteal cell functions by gonadotropin releasing hormone and its antagonist. Advanced Experimental Medical Biology 147 223-262.
36. Huston JP & Hasenöhrl RU 1995 The role of neuropeptides in learning: focus on the neurokinin substance P. Behavioral Brain Research 66 117-127.
37. Ikeda M, Taga M, Sakakibara H, Minaguchi H, Ginsburg E & Vonderhaar BK 1996 Gene expression of gonadotropin-releasing hormone in early pregnant rat and steroid hormone exposed mouse uteri. Journal of Endocrinological Investigation 19 708-713.
38. Imai A, Ohno T, Iida K, Fuseya T, Furui T & Tamaya T 1994 Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Gynecologic Oncology 55 114-118.
39. Imai A, Takagi H, Horibe S, Fuseya T & Tamaya T 1996 Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors. Journal of Clinical Endocrinology and Metabolism 81 3249-3253.
40. Imai A, Takagi A, Horibe S, Takagi H & Tamaya T 1998 Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin- releasing hormone receptor in endometrial cancer cells. International Journal of Oncology 13 97-100.
41. Irmer G, Burger C, Ortmann O, Schulz KD & Emons G 1994 Expression of luteinizing hormone releasing hormone and its mRNA in human endometrial cancer cell lines. Journal of Clinical Endocrinology and Metabolism 79 916-919.
42. Irmer G, Bürger C, Müller R, Ortmann O, Peter U, Kakar SS, Neill JD, Schulz KD & Emons G 1995 Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Research 55 817-822.
43. Jeske NA, Glucksman MJ & Roberts JL 2004 Metalloendopeptidase EC3.4.24.15 is constitutively released from the exofacial leaflet of lipid rafts in GT1-7 cells. Journal of Neurochemistry 90 819-828.
44. Jia YX, Yang JH, Pan CS, Geng B, Zhang J, Xiao Y, Gerns H, Yang J, Chang JK, Wen JK et al. 2006 Intermedin 1-53 protects the heart against isoproterenol-induced ischaemic injury in rats. European Journal of Pharmacology 549 117-123.
45. Jungwirth A, Schally AV, Halmos G, Groot K, Szepeshazi K, Pinski J & Armatis P 1998 Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II. Cancer 82 909-917.
46. Kakar SS, Grizzle WE & Neill JD 1994 The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Molecular and Cellular Endocrinology 106 145-149.
47. Kang SK, Cheng KW, Ngan ES, Chow BK, Choi KC & Leung PC 2000 Differential expression of human gonadotropin-releasing hormone receptor gene in pituitary and ovarian cells. Molecular and Cellular Endocrinology 162 157-166.
48. Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Westphal G, Halmos G & Engel JB 2005 Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue. Cancer Research 65 5857-5863.
49. Kim SI, Grum-Tokars V, Swanson TA, Cotter EJ, Cahill PA, Roberts JL, Cummins PM & Glucksman MJ 2003 Novel roles of neuropeptide processing enzymes: EC3.4.24.15 in the neurome. Journal of Neuroscience Research 74 456-467.
50. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L & Sylvester R 2001 Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. Journal of Clinical Oncology 19 343-353.
51. Koob GF 1996 Drug addiction: the yin and yang of hedonic homeostasis. Neuron 16 893-896.
52. Kottler ML, Starzec A, Carre MC, Lagarde JP, Martin A & Counis R 1997 The genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancer. International Journal of Cancer 71 595-599.
53. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E et al. 1998 Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281 1640-1645.
54. Kreeger JS & Larson AA 1996 The substance P amino-terminal metabolite substance P(1-7), administered peripherally, prevents the development of acute morphine tolerance and attenuates the expression of withdrawal in mice. Journal of Pharmacology and Experimental Therapeutics 279 662-667.
55. Krsmanovic LZ, Martinez-Fuentes AJ, Arora KK, Mores N, Navarro CE, Chen HC, Stojilkovic SS & Catt KJ 1999 Autocrine regulation of gonadotropin-releasing hormone secretion in cultured hypothalamic neurons. Endocrinology 140 1423-1431.
56. Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G, Laberge JG, Emond JP, Fazekas AT, Raynaud JP et al. 1982 New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clinical and Investigative Medicine 5 267-275.
57. Lasdun A, Reznik S, Molineaux CJ & Orlowski M 1989 Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hormone. Journal of Pharmacology and Experimental Therapeutics 251 439-447.
58. Latouche J, Crumeyrolle-Arias M, Jordan D, Kopp N, Augendre-Ferrante B, Cedard L & Haour F 1989 GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology 125 1739-1741.
59. Lau HL, Zhu XM, Leung PC, Chan LW, Chen GF, Chan PS, Yu KL & Chan FL 2001 Detection of mRNA expression of gonadotropin-releasing hormone and its receptor in normal and neoplastic rat prostates. International Journal of Oncology 19 1193-1201.
60. Lembeck F & Holzer P 1979 Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn-Schmiedeberg's Archives of Pharmacology 310 175-183.
61. Leung PCK, Cheng CK & Zhu X-M 2003 Multi-factorial role of GnRH-I and GnRH-II in the human ovary. Molecular and Cellular Endocrinology 202 145-153.
62. Lew RA, Tetaz TJ, Glucksman MJ, Roberts JL & Smith AI 1994 Evidence for a two-step mechanism of gonadotropin-releasing hormone metabolism by prolyl endopeptidase and metalloendopeptidase EC 3.4.24.15 in ovine hypothalamic extracts. Journal of Biological Chemistry 269 12626-12632.
63. Lijnen PJ & Petrov VV 2003 Role of intracardiac renin-angiotensin-aldosterone system in extracellular matrix remodeling. Methods and Findings in Experimental and Clinical Pharmacology 25 541-564.
64. Limonta P, Dondi D, Moretti RM, Maggi R & Motta M 1992 Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. Journal of Clinical Endocrinology and Metabolism 75 207-212.
65. Limonta P, Dondi D, Moretti RM, Fermo D, Garattini E & Motta M 1993 Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. Journal of Clinical Endocrinology and Metabolism 76 797-800.
66. Limonta P, Moretti RM, Marelli MM, Dondi D, Parenti M & Motta M 1999 The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, signal transduction pathway. Endocrinology 140 5250-5256.
67. Limonta P, Moretti RM, Marelli MM & Motta M 2003 The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. Frontiers in Neuroendocrinology 24 279-295.
68. Loop SM, Gorder CA, Lewis SM, Saiers JH, Drivdahl RH & Ostenson RC 1995 Growth inhibition of human prostate tumor cells by an agonist of gonadotrophin-releasing hormone. Prostate 26 179-188.
69. Meunier JC 1997 Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. European Journal of Pharmacology 340 1-15.
70. Millar RP 2005 GnRHs and GnRH receptors. Animal Reproduction Science 88 5-28.
71. Mimeault M, Quirion R, Dumont Y, St-Pierre S & Fournier A 1992 Structure-activity study of hCGRP8-37, a calcitonin gene-related peptide receptor antagonist. Journal of Medicinal Chemistry 35 2163-2168.
72. Minaretzis D, Alper MM, Oskowitz SP, Lobel SM, Mortola JF & Pavlou SN 1995 Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells. American Journal of Obstetrics and Gynecology 172 1518-1525.
73. Montiel JL, Cornille F, Roques BP & Noble F 1997 Nociceptin/orphanin FQ metabolism: role of aminopeptidase and endopeptidase 24.15. Journal of Neurochemistry 68 354-361.
74. Moretti RM, Montagnani Marelli M, Van Groeninghen JC & Limonta P 2002 Locally expressed LHRH receptors mediate the oncostatic and antimetastatic activity of LHRH agonists on melanoma cells. Journal of Clinical Endocrinology and Metabolism 87 3791-3797.
75. Müller FO, Terblanchè J, Schall R, van Zyl Smit R, Tucker T, Marais K, Groenewoud G, Porchet HC, Weiner H & Hawarden D 1997 Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. British Journal of Clinical Pharmacology 44 335-341.
76. Murdoch WJ 1995 Immunolocalization of a gonadotropin-releasing hormone receptor site in murine endometrium that mediates apoptosis. Cell and Tissue Research 282 527-529.
77. Murphey LJ, Gainer JV, Vaughan DE & Brown NJ 2000 Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 102 829-832.
78. Murphey LJ, Malave HA, Petro J, Biaggioni I, Byrne DW, Vaughan DE, Luther JM, Pretorius M & Brown NJ 2006 Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans. Journal of Pharmacology and Experimental Therapeutics 318 1287-1292.
79. Nakayama Y, Takano Y, Shimohigashi Y, Tanabe S, Fujita T, Kamiya H & Tsujimoto G 2000 Pharmacological characterization of a novel AVP(4-9) binding site in rat hippocampus. Brain Research 858 416-423.
80. Nohr D, Schäfer MK, Persson S, Romeo H, Nyberg F, Post C, Ekström G & Weihe E 1999 Calcitonin gene-related peptide gene expression in collagen-induced arthritis is differentially regulated in primary afferents and motoneurons: influence of glucocorticoids. Neuroscience 93 759-773.
81. Nyberg F & Silberring J 1990 Conversion of the dynorphins to Leuenkephalin in human spinal cord. Progress in Clinical and Biological Research 328 261-265.
82. Nyberg F, Kankaanranta S, Brostedt P & Silberring J 1991 Purification and characterization of endoproteases from human choroid plexus cleaving prodynorphin-derived opioid peptides. Brain Research 552 129-135.
83. Ohno T, Imai A, Furui T, Takahashi K & Tamaya T 1993 Presence of gonadotropin-releasing hormone and its messenger ribonucleic acid in human ovarian epithelial carcinoma. American Journal of Obstetrics and Gynecology 169 605-610.
84. Orlowski M, Michaud C & Chu TG 1983 A soluble metalloendopeptidase from rat brain. Purification of the enzyme and determination of specificity with synthetic and natural peptides. European Journal of Biochemistry 135 81-88.
85. Orlowski M, Reznik S, Ayala J & Pierotti AR 1989 Endopeptidase 24.15 from rat testes. Isolation of the enzyme and its specificity toward synthetic and natural peptides, including enkephalin-containing peptides. Biochemical Journal 261 951-958.
86. Peng C, Fan NC, Ligier M, Vannanen J & Leung PCK 1994 Expression and regulatin of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulose-luteal cells. Endocrinology 135 1740-1746.
87. Pierotti AR, Lasdun A, Ayala JM, Roberts JL & Molineaux CJ 1991 Endopeptidase-24.15 in rat hypothalamic/pituitary/gonadal axis. Molecular and Cellular Endocrinology 76 95-103.
88. Pineau C, McCool S, Glucksman MJ, Jegou B & Pierotti AR 1999 Distribution of thimet oligopeptidase (E.C. 3.4.24.15) in human and rat testes. Journal of Cell Science 112 3455-3462.
89. Plosker GL & Brogden RN 1994 Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs 48 930-967.
90. Powell JF, Reska-Skinner SM, Prakash MO, Fischer WH, Park M, Rivier JE, Craig AG, Mackie GO & Sherwood NM 1996 Two new forms of gonadotropin-releasing hormone in a protochordate and the evolutionary implications. PNAS 93 10461-10464.
91. Raga F, Casañ EM, Kruessel JS, Wen Y, Huang HY, Nezhat C & Polan ML 1998 Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biology of Reproduction 59 661-669.
92. Ramakrishnappa N, Rajamahendran R, Lin Y-M & Leung PCK 2005 GnRH in non-hypothalamic reproductive tissues. Animal Reproduction Science 88 95-113.
93. Rastogi RK, Di Fiore MM, D' Aniello A, Iela L & Fiorentino M 2002 GnRH in the invertebrates: an overview. Progress in Brain Research 141 19-29.
94. Ray K, Hines CS, Coll-Rodriguez J & Rodgers DW 2004 Crystal structure of human thimet oligopeptidase provides insight into substrate recognition, regulation, and localization. Journal of Biological Chemistry 279 20480-20489.
95. Rossi GC, Leventhal L, Bolan E & Pasternak GW 1997 Pharmacological characterization of orphanin FQ/nociceptin and its fragments. Journal of Pharmacology and Experimental Therapeutics 282 858-865.
96. Sampaio WO, Nascimento AA & Santos RA 2003 Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. American Journal of Physiology. Heart and Circulatory Physiology 284 H1985-H1994.
97. Santos RA, Ferreira AJ & Simões E Silva AC 2008 Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Experimental Physiology 93 519-527.
98. Schally AV 1999 Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 20 1247-1262.
99. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL & Halmos G 2001 Hypothalamic hormones and cancer. Frontiers in Neuroendocrinology 22 248-291.
100. Schneider F, Tomek W & Grundker C 2006 Gonadotropin-releasing hormone (GnRH) and its natural analogues: a review. Theriogenology 66 691-709.
101. Shaikh MB, Steinberg A & Siegel A 1993 Evidence that substance P is utilized in medial amygdaloid facilitation of defensive rage behavior in the cat. Brain Research 625 283-294.
102. Sharpe LG & Jaffe JH 1989 Captopril and capsaicin modify opioid withdrawal in the morphine-dependent rat. Pharmacology, Biochemistry, and Behavior 33 899-902.
103. Skidgel RA, Engelbrecht S, Johnson AR & Erdös EG 1984 Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides 5 769-776.
104. Sogani PC & Fair WR 1987 Treatment of advanced prostatic cancer. Urologic Clinics of North America 14 353-371.
105. Stewart JM, Hall ME, Harkins J, Frederickson RC, Terenius L, Hökfelt T & KrivoyWA 1982 A fragment of substance P with specific central activity: SP(1-7). Peptides 3 851-857.
106. Swanson TA, Kim SI, Myers M, Pabon A, Philibert KD, Wang M & Glucksman MJ 2004 The role of neuropeptide processing enzymes in endocrine (prostate) cancer: EC 3.4.24.15 (EP 24.15). Protein and Peptide Letters 11 471-478.
107. Tieva A, Stattin P, Wikström P, Bergh A & Damber JE 2001 Gonadotropin-releasing hormone receptor expression in the human prostate. Prostate 47 276-284.
108. Tiong JD, Pakiam JG & Wray S 2004 Gonadotropin releasing hormone-1 expression in incisors of mice. Endocrinology 145 3608-3612.
109. Tsai PS 2006 Gonadotropin-releasing hormone in invertebrates: structure, function and evolution. General and Comparative Endocrinology 148 48-53.
110. Tullai JW, Cummins PM, Pabon A, Roberts JL, Lopingco MC, Shrimpton CN, Smith AI, Martignetti JA, Ferro ES & Glucksman MJ 2000 The neuropeptide processing enzyme EC 3.4.24.15 is modulated by protein kinase A phosphorylation. Journal of Biological Chemistry 275 36514-36522.
111. Vincze B, Pályi I, Daubner D, Kremmer T, Számel I, Bodrogi I, Sugár J, Seprödi J, Mezö I, Teplán I et al. 1991 Influence of luteinizing hormone-releasing hormone agonists on human mammary carcinoma cell lines and their xenografts. Journal of Steroid Biochemistry and Molecular Biology 38 119-126.
112. Walters K, Chin YP & Wu TJ 2007 A processed metabolite of luteinizing hormone-releasing hormone has proliferative effects in endometrial cells. American Journal of Obstetrics and Gynecology 196 33e1-33e5.
113. Walters K, Wegorzewska IN, Chin YP, Parikh MG & Wu TJ 2008 Luteinizing hormone-releasing hormone I (LHRH-I) and its metabolite in peripheral tissues. Experimental Biology and Medicine 233 123-130.
114. Wang XC & Burbach JP 1986 Formation of metabolites of [Arg8] vasopressin (AVP) by brain peptidases. Conversion of the intermediate [Cyt6]AVP-(3-9). FEBS Letters 197 164-168.
115. Warner FJ, Smith AI, HooperNM& Turner AJ 2004 Angiotensin-converting enzyme-2: a molecular and cellular perspective. Cellular and Molecular Life Sciences 61 2704-2713.
116. de Wied D, Diamant M & Fodor M 1993 Central nervous system effects of the neurohypophyseal hormones and related peptides. Frontiers in Neuroendocrinology 14 251-302.
117. Wiktelius D, Khalil Z & Nyberg F 2006 Modulation of peripheral inflammation by the substance P N-terminal metabolite substance P1-7. Peptides 27 1490-1497.
118. Wolfahrt S, Kleine B & Rossmanith WG 1998 Detection of gonadotrophin releasing hormone and its receptor mRNA in human placental trophoblasts using in situ reverse transcription-polymerase chain reaction. Molecular Human Reproduction 4 999-1006.
119. Wray S 2002 Development of gonadotropin-releasing hormone-I neurons. Frontiers in Neuroendocrinology 23 292-316.
120. Wu TJ, Pierotti AR, Jakubowski M, Sheward WJ, Glucksman MJ, Smith AI, King JC, Fink G & Roberts JL 1997 Endopeptidase EC 3.4.24.15 presence in the rat median eminence and hypophysial portal blood and its modulation of the luteinizing hormone surge. Journal of Neuroendocrinology 9 813-822.
121. Wu TJ, Mani SK, Glucksman MJ & Roberts JL 2005 Stimulation of luteinizing hormone-releasing hormone (LHRH) gene expression in GT1-7 cells by its metabolite, LHRH-(1-5). Endocrinology 146 280-286.
122. Wu TJ, Glucksman MJ, Roberts JL &Mani SK 2006 Facilitation of lordosis in rats by a metabolite of luteinizing hormone releasing hormone. Endocrinology 147 2544-2549.
123. Wu HM, Wang HS, Huang HY, Soong YK, MacCalman CD & Leung PC 2009 GnRH signaling in intrauterine tissues. Reproduction 137 769-777.
124. Yano T, Yano N, Matsumi H, Morita Y, Tsutsumi O, Schally AV & Taketani Y 1997 Effect of luteinizing hormone-releasing hormone analogs on the rat ovarian follicle development. Hormone Research 48 35-41.
125. Zubrzycka M & Janecka A 2000 Substance P: transmitter of nociception. Endocrine Regulations 34 195-201.